Immunome Stock Hits Day Low of $14.71 Amid Price Pressure

Immunome, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 9.71%. The stock reached an intraday low of USD 14.71, reflecting a challenging trading session compared to the S&P 500, which fell by only 1.17%.
Over the past week, Immunome has seen a decrease of 6.35%, while its performance over the last month remains positive at 23.99%. Year-to-date, the stock has shown a robust gain of 44.54%, significantly outperforming the S&P 500's 15.13% increase. In the longer term, Immunome's three-year performance stands at an impressive 267.22%, compared to the S&P 500's 79.59%.

Despite the recent downturn, the company has reported positive developments, including a higher net profit of USD -85.04 million for the first half of the year and a notable reduction in raw material costs. However, it continues to face challenges with a negative EBITDA and a return on equity of -66.22%. With institutional holdings at 100%, the stock remains under close scrutiny by knowledgeable investors.